Group: Deep Organ Tumours
Lung & Peribronchial Tumours
Lung and peribronchial sites are technically demanding because of the electrical conductivity of air-filled tissue and respiratory motion. The number of publications in the corpus is limited and the area is largely at an early research stage.
Clinical publications: randomized, prospective and retrospective studies, case series and case reports. Preclinical publications: animal, in vitro, modelling and experimental biophysics studies.
Health Technology Assessments in This Area
This portal counts the volume of the literature; it does not assess whether a procedure is effective. The bodies below do make that assessment, and their conclusions are independent of how large the literature is: a large literature does not mean the evidence was found sufficient.
- NICE · 2013 · IRE in primary lung cancer and lung metastases (HealthTech htg302, formerly IPG441)
The full set with citations is on the Regulatory Documents page. The portal does not interpret these reports on its own behalf; for the current decision consult the issuing body’s own publication.
Clinical and Technical Data Reported in the Publications
The sum of the fields reported in the full text of the 18 publications in this area. The numbers are summed, not interpreted.
The totals are not a count of unique patients: the same cohort may have been reported in more than one publication.
Literature Status by Method
Publication count, clinical and preclinical split, literature volume and publication span for each clinical method. The badges at the top of the page summarise the IRE and ECT records separately; the full split by method is here.
Electrochemotherapy (ECT)
Exploratory / low-volume literaturethreshold 1/4 records
Clinical and preclinical split of that figure: 0 clinical, 1 preclinical.
2002–2025
Irreversible electroporation (IRE)
Exploratory / low-volume literaturethreshold 2/11 records
Clinical and preclinical split of that figure: 0 clinical, 2 preclinical.
2012–2026
Other electroporation applications
This set does not name a single clinical method; no literature volume is assigned.
2019–2023
Mechanisms Mentioned in Abstracts
The figure is the number of abstracts mentioning the mechanism. A mention does not mean it was demonstrated in that study.
Study Type Distribution
The percentage gives the share of the whole area.
| Study type | Publications | Share within this area |
|---|---|---|
| Clinical Study | 3 | 17% |
| Case Report | 1 | 6% |
| Review | 2 | 11% |
| Animal Study | 9 | 50% |
| In Vitro Study | 3 | 17% |
Publication Table
18 publication records sorted by study design. Click a title to open the citation, mechanism and full abstract drawer.
Classifications are generated automatically and can be wrong for individual records. Methodology
| Regime | Publication | Year | Study type | Model | Mechanism | Patients / lesions | Device | Agent and route | Reported outcome | Abstract |
|---|---|---|---|---|---|---|---|---|---|---|
| IRE | Kodama et al · Journal of Vascular and Interventional Radiology | 2016 | Clinical Study | Animal (In Vivo) | Reversible Membrane Permeabilisation, Irreversible Pore Formation and Cell Death | – | – | – | – | No. 585 Managing chest tubes following lung biopsy: how to read a water seal device and algorithm for same day discharge Feasibility and acute safety following catheter directed endoluminal … |
| IRE | Solomon SB · – | 2016 | Clinical Study | Human | Reversible Membrane Permeabilisation, Irreversible Pore Formation and Cell Death | 10 | NanoKnife | – | – | This publication has no abstract. |
| IRE | Ricke et al · Cardiovasc Intervent Radiol | 2015 | Clinical Study | Human | Irreversible Pore Formation and Cell Death, Reversible Membrane Permeabilisation | 23 / 23 | NanoKnife | – | complete response 7 count (23 lesions) | Purpose: To assess safety and efficacy of irreversible electroporation (IRE) of lung malignancies. Materials and methods: Patients with primary and secondary lung malignancies and preserved … |
| IRE | Usman et al · Med Sci Monit | 2012 | Case Report | Human | Irreversible Pore Formation and Cell Death, Reversible Membrane Permeabilisation | 2 / 2 | Angiodynamics IRE generator | – | – | Background: Percutaneous irreversible electroporation (IRE) of lung tumors is a new minimally invasive technique which has recently been used in the treatment of soft tissue tumors. Case rep… |
| Other EP | Lassandro · Pol J Radiol | 2023 | Review | Literature Analysis | Reversible Membrane Permeabilisation, Irreversible Pore Formation and Cell Death | – | – | – | – | Thermal ablation is a minimally invasive technology used to treat many types of tumors, including lung cancer. Specifically, lung ablation has been increasingly performed for unsurgical fit … |
| ECT | Jahangeer et al · Cancer Treat Rev | 2013 | Review | Human | – | – | – | bleomycin | – | Lung cancer remains the most common cancer diagnosed worldwide and has one of the lowest survival rates of all cancers. Surgery remains the only curative treatment option but because most pa… |
| IRE | Kim · PLoS One | 2026 | Animal Study | Animal (In Vivo) | Irreversible Pore Formation and Cell Death, Mitochondrial Dysfunction and Oxidative Stress | – | BTX940, Petri pulser (45-0130), BTX940 pulse generator | – | – | This study aimed to optimize irreversible electroporation (IRE) parameters to enhance intracellular injury, specifically targeting nuclear and mitochondrial structures that are insufficientl… |
| IRE | Zhang et al · Transl Res | 2026 | Animal Study | Animal (In Vivo) | Irreversible Pore Formation and Cell Death, Reversible Membrane Permeabilisation | – / 30 | WK-WN-K-B2Plus, broadband steep pulse ablation device | – | – | Objective: To assess the feasibility and safety of bronchoscopy-guided synergistic pulsed irreversible electroporation (S-IRE) for ablating pulmonary tissues. Methods: Three Bama pigs underw… |
| ECT | Radzevičiūtė-Valčiukė et al · Pharmaceutics | 2025 | Animal Study | Animal (In Vivo) | Increased Intracellular Bleomycin Accumulation, Increased Intracellular Cisplatin Accumulation | – | – | calcium chloride · intratumoural | complete response 1 count | Background/Objectives: Electrochemotherapy (ECT) is a reliable and potent technique for managing primary tumors; however, significant efforts are being made to characterize and improve the s… |
| IRE | Fang · Front Immunol | 2025 | Animal Study | Animal (In Vivo) | Irreversible Pore Formation and Cell Death, Reversible Membrane Permeabilisation | – | BioRad electroporator | – | – | Irreversible electroporation (IRE) is a relatively new, non-thermal ablation technology for cancer treatment that requires further investigation to optimize its therapeutic efficacy. To impr… |
| Other EP | Meininger et al · Ann Biomed Eng | 2023 | Animal Study | Animal (In Vivo) | – | – | RheOx | – | – | Pulsed electric field (PEF) technologies treat many types of tissue. Many systems mandate synchronization to the cardiac cycle to avoid the induction of cardiac arrhythmias. Significant diff… |
| IRE | Fujimori et al · Bioelectricity | 2021 | Animal Study | Animal (In Vivo) | Irreversible Pore Formation and Cell Death, Reversible Membrane Permeabilisation | – | NanoKnife, Emprint | – | – | Background: This study investigated the sparing of the extracellular matrix (ECM) and blood vessels at the site of lung irreversible electroporation (IRE), and its impact on postablation T c… |
| IRE | Kodama et al · J Thorac Cardiovasc Surg | 2018 | Animal Study | Animal (In Vivo) | Increased Intracellular Cisplatin Accumulation, Reversible Membrane Permeabilisation | – | NanoKnife | cisplatin · intravenous | – | Objective: To evaluate the feasibility of catheter-based endobronchial electroporation for the treatment of peribronchial tumors and assess the incidence of treatment-related adverse events.… |
| IRE | Song · World J Surg Oncol | 2018 | Animal Study | Animal (In Vivo) | Apoptosis Induction, Reversible Membrane Permeabilisation | – | energy-controllable steep pulse therapeutic apparatus | – | tumour volume change 47.88 cm³ (9 animals) | Background: Steep pulse therapy can irreversible electrically brackdown of tumor membrance and cause cell death. In previous studies, we investigated the effect of steep pulsed electroporati… |
| ECT | Salomskaite-Davalgiene et al · Medicina (Kaunas) | 2002 | Animal Study | Animal (In Vivo) | Increased Intracellular Bleomycin Accumulation, Haemostasis and Bleeding Control | – | – | bleomycin · intravenous | – | Under the influence of strong electric fields the permeability of tumor cell membranes to poor permeating drugs increases and as a result the tumor growth is inhibited. This new tumor treatm… |
| Other EP | Kim et al · Biochem Biophys Res Commun | 2019 | In Vitro Study | Cell Culture | Reversible Membrane Permeabilisation, Transmembrane Potential Change | – | BTX ECM830 | other · other route | – | Electroporation is used for cancer therapy to efficiently destroy cancer tissues by transferring anticancer drugs into cancer cells or by irreversible tumor ablation without resealing pores.… |
| ECT | DRĄG-ZALESIŃSKA et al · Anticancer Res | 2019 | In Vitro Study | Cell Culture | Increased Intracellular Cisplatin Accumulation, Apoptosis Induction | – | BTX ECM830 | cisplatin | cell viability 35% (100 not reported) | Background/aim: Small cell lung cancer (SCLC) originates from neuroendocrine branchial cells (15-20%). It is regarded as distinct from other lung cancers due to its biological and clinical f… |
| IRE | Song et al · Int J Clin Exp Med | 2014 | In Vitro Study | Cell Culture | Apoptosis Induction, Reversible Membrane Permeabilisation | – | energy controllable steep pulse therapeutic apparatus | – | – | To explore the mechanisms for steep pulse irreversible electroporation technology to kill the lung cancer cell L9981. The apoptosis, cells mitochondrial membrane potential, internal PH chang… |
No publication matches these filters.
Limitations
Publication volume is not clinical efficacy or evidence quality. It describes how much literature exists in the area and of what kind; it does not indicate how strongly the treatment is supported, guideline endorsement or regulatory status.
Patient totals are not a count of unique patients. The same cohort may have been reported in more than one publication; the totals are not a meta-analysis.
How the corpus was assembled, the tier thresholds, the definition of a clinical publication and why methods are counted separately: Literature Map.